Clinical trials: Contrast-Induced Nephropathy
Acute Kidney Injury, Renal Insufficiency
Novel Biomarkers for Risk Prediction of Contrast-Induced Acute Kidney Injury Post Coronary Angiography
Contrast-induced acute kidney injury (CI-AKI) has been recognized as the third most common cause of hospital acquired AKI, after hypotension-associated hypo-perfusion and post-operative AKI.
- Conditions
- Acute Kidney Injury, Renal Insufficiency, Kidney Diseases
- Trial name
- NORDICA (NCT02263820)
- Where
- United States
- Volunteers
- 185 people
- Sponsor
- Sapere Bio
Patients at Risk for Developing Contrast-induced Nephropathy
DyeVert™ System for Contrast Monitoring in At-Risk Patients Undergoing Angiography: A Real-World Registry
The purpose of this registry-based study is to evaluate the ongoing, real-world clinical performance and safety of commercially available DyeVert Systems during typical clinical use for patients undergoing coronary or peripheral…
- Trial name
- DyeMINISH (NCT03825094)
- Testing
- DyeVert™ Contrast Reduction Systems
- Where
- 11 sites in United States
- Volunteers
- 10,000 people
- Sponsor
- Osprey Medical, Inc
Renal Insufficiency
Renal Safety Evaluation After Dotarem®-Enhanced MRI
Although there is a well documented risk of acute renal failure with the iodinated contrast agents, the implication of intravenous gadolinium-based contrast agents in nephrotoxicity remains controversial.
- Trial name
- RESCUE (NCT00650845)
- Testing
- Dotarem®-enhanced MRI, non-enhanced MRI
- Where
- 15 sites in Belgium, France and 2 more
- Volunteers
- 135 people
- Sponsor
- Guerbet
Contrast Induced Nephropathy
Patients With Renal Impairment Undergoing CT
The purpose of the study is to compare the incidence of contrast induced nephrotoxicity following the administration of Isovue or Visipaque in patients with mild to moderate renal impairment who undergo a clinically indicated IV…
- Trial name
- NCT00292487
- Testing
- Iopamidol 370 mgI/mL
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Bracco Diagnostics, Inc
Contrast Induced Acute Kidney Injury
Study of APX-115 in Contrast Induced Acute Kidney Injury in Subjects Undergoing PCI
This phase 2 study is to assess the safety and efficacy of APX-115 active doses in Contrast Induced Acute Kidney Disease compared to placebo following multiple oral dosing in patients with undergoing percutaneous coronary…
- Trial name
- NCT05758896
- Testing
- Isuzinaxib (APX-115)
- Where
- 14 sites in United States, South Korea
- Volunteers
- 218 people
- Sponsor
- Aptabio Therapeutics, Inc.
Fibrosis, Kidney Failure
Risk of Nephrogenic Systemic Fibrosis (NSF) in Patients With Moderate Renal Insufficiency After the Administration of Magnevist
Assess potential risk for NSF in subjects with renal impairment (moderate) post magnevist injection. Subjects will be screened within 48 hours of previously scheduled MRI, those meeting the enrollment criteria will be enrolled…
- Conditions
- Fibrosis, Kidney Failure, Renal Insufficiency
- Trial name
- NCT00744939
- Testing
- Gadopentetate dimeglumine (Magnevist, BAY86-4882)
- Where
- 26 sites in United States
- Volunteers
- 168 people
- Sponsor
- Bayer
Contrast-Induced Acute Kidney Injury
Deferiprone for the Prevention of Contrast-Induced Acute Kidney Injury
The primary objective of this trial is to assess the impact of CRMD-001 on markers of contrast-induced acute kidney injury (AKI) in high-risk patients with chronic kidney disease (CKD) undergoing coronary angiography and PCI.
- Trial name
- NCT01146925
- Testing
- CRMD-001-Deferiprone
- Where
- 8 sites in United States
- Volunteers
- 60 people
- Sponsor
- CorMedix Therapeutics
Contrast-induced Nephropathy, Chronic Kidney Diseases
Multi-Center Trial Utilizing Low Frequency Ultrasound in the Prevention of Post-Contrast Acute Kidney Injury
Multi-center randomized trial to assess the safety and performance of low-frequency therapeutic ultrasound for maintaining renal function after contrast exposure.
- Trial name
- LOTUS (NCT04877847)
- Testing
- Low-frequency therapeutic ultrasound (LOTUS), LOTUS System with Ultrasound Disabled
- Where
- 4 sites in United States
- Volunteers
- 2 people
- Sponsor
- Sonogenix
Acute Kidney Injury (Nontraumatic)
Study of CXA-10 in Healthy Volunteers
This will be the first-in-human (FIH) study with CXA-10. The main purpose of this trial is to demonstrate the tolerability, safety and pharmacokinetics (PK) of CXA-10 at various incremental doses, and to demonstrate the safety…
- Trial name
- NCT02127190
- Testing
- CXA-10 emulsion
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Complexa, Inc.
Contrast-induced Nephropathy, Coronary Angiography
Relative Bioavailability of CE-Iohexol (Captisol-enabled™ Iohexol) Injection and Omnipaque™ Injection
This study is designed to compare the bioavailability of the test Product(CE-Iohexol Injection) and the reference product Iohexol Injection (Omnipaque™) following intravenous injection in normal healthy volunteers.
- Trial name
- NCT03869983
- Testing
- Omnipaque™ (iohexol) Injection, CE-Iohexol
- Where
- Canada
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- CyDex Pharmaceuticals, Inc.
Contrast-induced Nephropathy
Comparison of Captisol-Enabled™ Iohexol and Omnipaque™ in Patients With Impaired Renal Function Undergoing Coronary Angiography
Randomized parallel group study comparing the renal safety of Captisol-Enabled™ Iohexol (CE-Iohexol) Injection and Omnipaque™ (Iohexol) Injection in patients with impaired renal function undergoing coronary angiography.
- Trial name
- NCT04627831
- Testing
- CE-Iohexol, Iohexol
- Sponsor
- Ligand Pharmaceuticals
Contrast Induced Kidney Injury.
Evaluation of Sodium Bicarbonate to Reduce the Incidence of Contrast Induced Chronic Kidney Injury in Patients With Kidney Disease
Patients with Stage 3B, 4,or 5 Chronic Kidney Disease who are to undergo an angiography procedure with contrast agent will be asked if they are willing to join the trial.
- Trial name
- BOSS (NCT00930436)
- Testing
- sodium bicarbonate
- Where
- 17 sites in United States
- Volunteers
- 391 people
- Sponsor
- MD Scientific
Acute Kidney Injury
Efficacy and Safety of Deferiprone in Patients With Chronic Kidney Disease Undergoing a Cardiac Catheterization and Receiving Contrast Agent
This trial will evaluate whether treatment with CRMD001 (unique formulations of the iron chelator, Deferiprone) will reduce morbidity and mortality in subjects with Chronic Kidney Disease (CKD) and additional risk factors.
- Trial name
- NCT01391520
- Testing
- deferiprone
- Sponsor
- CorMedix Therapeutics
Coronary Artery Disease (CAD), Renal Impairment
Renal Effects of Three Iodinated Contrast Media (CM) in Patients at Risk Undergoing Coronary Angiography
The study is to evaluate and compare the effects on kidney function of three iodinated contrast media (CM) in patients at risk of kidney damage evaluating serum creatinine (Scr) concentrations up to three days after CM…
- Conditions
- Coronary Artery Disease (CAD), Renal Impairment, Diabetes Mellitus
- Trial name
- NCT00335101
- Testing
- Iodixanol, Ioversol, Iopromide
- Where
- 2 sites in United States, Germany
- Sponsor
- GE Healthcare
Renal Artery Stenosis
A Safety & Efficacy Clinical Study to Evaluate the Narrowing of the Renal Arteries While Using Gadodiamide
Magnetic Resonance Angiography (MRA) is an examination similar to Magnetic Resonance Imaging (MRI) which uses a magnetic field and a contrast medium when needed to visualize blood flow in the arterial vessels throughout the body.
- Trial name
- NCT00209391
- Testing
- Gadodiamide Injection
- Where
- Germany
- Volunteers
- 395 people
- Sponsor
- GE Healthcare
AKI, Contrast-induced Nephropathy
Establishing Clinical Utility of a New Diagnostic Test in Patients Undergoing Cardiac Catheterization
This study will collect high-quality randomized controlled data across the U.S. from practicing cardiologists performing invasive/interventional procedures and determine how they currently manage patients at risk for CIN and how…
- Trial name
- NCT04266834
- Testing
- Experimental Arm
- Where
- United States
- Volunteers
- 157 people, healthy volunteers welcome
- Sponsor
- Qure Healthcare, LLC
Chronic Renal Insufficiency, Diabete Mellitus
Safety Study of GE-145 320 mg I/mL Injection vs. Iopamidol 370 mg I/mL in Elderly Subjects Undergoing Coronary Procedure
To evaluate cardio-renal and overall safety profile of GE 145 320 mg I/ml Injection when compared to iopamidol 370 mg I/mL. The study will focus on elderly subjects with either chronic renal insufficiency, or diabetes mellitus…
- Conditions
- Chronic Renal Insufficiency, Diabete Mellitus, Congestive Heart Failure
- Trial name
- NCT01252810
- Testing
- GE-145
- Where
- United States
- Volunteers
- 284 people
- Sponsor
- GE Healthcare
Kidney Diseases
Patients With Renal Impairment and Diabetes Undergoing Computed Tomography (CT)
The main purpose of this study is to compare the incidence of contrast induced nephrotoxicity following the administration of Isovue (iopamidol) or Visipaque in diabetic patients with moderate to severe chronic renal impairment…
- Trial name
- NCT00289614
- Testing
- Iopamidol 370 mgI/dL
- Where
- United States
- Volunteers
- 350 people
- Sponsor
- Bracco Diagnostics, Inc
Contrast Induced Nephropathy (CIN)
AVERT™ Clinical Trial for Contrast Media Volume Reduction and Incidence of CIN
The Osprey Medical AVERT System is indicated to reduce contrast media (CM) exposure to the kidneys during percutaneous coronary procedures thereby reducing the risk of contrast induced nephropathy (CIN).
- Trial name
- AVERT™ (NCT01976299)
- Testing
- AVERT
- Where
- 39 sites in United States, Australia and 1 more
- Volunteers
- 578 people
- Sponsor
- Osprey Medical, Inc
Coronary Artery Disease, Renal Impairment
Renal Effects of Two Iodinated Contrast Media in Patients at Risk Undergoing Coronary Angiography
The main purpose of this study is to evaluate and compare the effects on kidney function of two contrast media, the iso-osmolar iodixanol and the low-osmolar iopamidol in patients at risk of kidney damage associated with the…
- Trial name
- NCT00209430
- Testing
- Iodixanol 320 mgI/mL
- Where
- Sweden
- Volunteers
- 408 people
- Sponsor
- GE Healthcare